Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

(NASDAQ:GLTO), DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Recent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical Officer Pipeline of additional candidates advancing to the […]

Enphase Energy Begins Shipments of IQ9 Commercial Microinverters in the United States

(NasdaqGM:ENPH), FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced that it began production shipments of its IQ9N-3P(TM) Commercial Microinverter across the United States in late December 2025. The product is manufactured in the United States to support domestic content requirements and Foreign Entity

Hyperion DeFi Issues Letter to Shareholders

(NASDAQ:HYPD), LAGUNA HILLS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”) today issued a letter to shareholders from its Chief Executive Officer, Hyunsu Jung. To the shareholders of Hyperion DeFi, Inc.: Let me start by expressing my sincere gratitude to those sharing in our journey to

Zoom reinforces commitment to AI literacy with national student learning experience

(NASDAQ:ZM), SAN JOSE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — As artificial intelligence (AI) becomes a foundational skill for the future workforce, Zoom Communications, Inc. (NASDAQ: ZM) is reinforcing its commitment to AI literacy with Zoom Ahead: AI for Tomorrow's Leaders. This live national learning experience is designed to help students understand how AI can

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

(NasdaqGM:CNTB), – Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 – – Recruitment ongoing for Phase 2

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

(NasdaqGM:BCAX), Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 to further characterize ficerafusp alfa's profile in

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

(NASDAQ:KYTX), Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase

New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal

— Study highlights importance of cancer driver biology in translating results from lab to patients — — Findings validate proprietary OncoSLX Platform(TM), a pharmacogenetic approach that captures the full spectrum of drug biology — — Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 lossâ€'ofâ€'function cancers; expect to initiate Phase 1b/2a clinical trial

Scroll to Top